Tab Application Banner
  • Users Online: 1713
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
 
REVIEW ARTICLE
Ahead of Print

Safety of Cyclophosphamide Therapy in Autoimmune Rheumatic Diseases


1 Department of Rheumatology and Immunology, JSS Medical College, JSS Academy of Higher Education and Research, Mysuru, Karnataka, India
2 Department of Rheumatology, Tricolour Hospitals, Vadodara, Gujarat, India
3 Centre for Rheumatology, Calicut, Kerala, India

Correspondence Address:
Vinod Ravindran,
Centre for Rheumatology, Calicut, Kerala
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/injr.injr_28_19

Cyclophosphamide (CYC) is one of the most potent antineoplastic and immunosuppressant agents. It is used as a drug of choice in many organ-threatening manifestations of systemic autoimmune rheumatic diseases (AIRDs) such as lupus nephritis, antineutrophil cytoplasmic antibody-associated vasculitis, classical polyarteritis nodosa, and myositis. It is also used in connective tissue disease-related interstitial lung disease and Behcet's disease. However, its use may be limited by the toxicities including its adverse effects on gonads in the childbearing age group, severe infections, hemorrhagic cystitis, and malignancies associated with prolonged usage. As a result, mycophenolate, azathioprine, and rituximab have gained popularity over CYC as an induction and maintenance agent in many AIRDs. However, in the event of failure of aforementioned agents in aggressive rheumatic diseases or in a resource-limited setting, the usage of CYC continues to be a useful therapeutic strategy. In this review, we have appraised the adverse effects of CYC therapy in AIRDs which would help clinicians in taking informed decisions regarding CYC usage.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Subramanian R
    -  Pathak H
    -  Ravindran V
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed91    
    PDF Downloaded3    

Recommend this journal